Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis

Drug-resistant MS spasticity treatment with Sativex®add-on and driving ability

(2014) M. Freidel et al.   ACTA NEUROLOGICA SCANDINAVICA

Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis

(2014) Yahiya Y. Syed et al.   DRUGS

A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment

(2014) M. Serpell et al.   EUROPEAN JOURNAL OF PAIN

Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice

(2014) Peter Flachenecker et al.   EUROPEAN NEUROLOGY

Advances in the Management of MS Spasticity: Recent Observational Studies

(2014) Oscar Fernández   EUROPEAN NEUROLOGY

Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity

(2014) Peter Flachenecker et al.   EUROPEAN NEUROLOGY

Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis

(2014) Irene Moreno Torres et al.   Expert Review of Neurotherapeutics

Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany

(2014) Thomas Henze et al.   Health and Quality of Life Outcomes

Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity

(2014) Jürgen Koehler et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity

(2014) P. Browne et al.   NEUROLOGY

Impact of Sativex®on quality of life and activities of daily living in patients with multiple sclerosis spasticity

(2014) Rafael Arroyo et al.   Journal of Comparative Effectiveness Research

Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of life

(2013) P. Flachenecker et al.   ACTA NEUROLOGICA SCANDINAVICA

Costs and quality of life in multiple sclerosis patients with spasticity

(2013) J. Svensson et al.   ACTA NEUROLOGICA SCANDINAVICA

Driving performance in persons with mild to moderate symptoms of multiple sclerosis

(2013) Hannes Devos et al.   DISABILITY AND REHABILITATION

Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain

(2013) Antonio García-Merino   Expert Review of Neurotherapeutics

A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost–effectiveness in Germany

(2013) Peter Flachenecker   Expert Review of Neurotherapeutics

Spasticity in multiple sclerosis: results of a patient survey

(2013) C. Oreja-Guevara et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Cerebral palsy

(2013) Allan Colver et al.   LANCET

A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers

(2013) Colin Stott et al.   SpringerPlus

A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray

(2012) C. G. Stott et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray

(2012) C. G. Stott et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Troublesome Symptoms in Cancer Survivors: Fatigue, Insomnia, Neuropathy, and Pain

(2012) Deirdre R. Pachman et al.   JOURNAL OF CLINICAL ONCOLOGY

The Unique Features of Traumatic Brain Injury in Children. Review of the Characteristics of the Pediatric Skull and Brain, Mechanisms of Trauma, Patterns of Injury, Complications and Their Imaging Findings-Part 1

(2012) Pedro S. Pinto et al.   JOURNAL OF NEUROIMAGING

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis

(2012) Michael G. Serpell et al.   JOURNAL OF NEUROLOGY

Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial

(2012) Russell K. Portenoy et al.   JOURNAL OF PAIN

An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics

(2012) Jeremy R. Johnson et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Sativex® in multiple sclerosis spasticity: a cost–effectiveness model

(2012) John Slof et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity

(2012) Verena Isabell Leussink et al.   Therapeutic Advances in Neurological Disorders

Immune-mediated CNS diseases: A review on nosological classification and clinical features

(2011) Uwe K. Zettl et al.   AUTOIMMUNITY REVIEWS

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine

(2011) Philip Robson   Expert Opinion On Drug Safety

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis

(2011) Jaume Sastre-Garriga et al.   Expert Review of Neurotherapeutics

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)

(2011) W Notcutt et al.   Multiple Sclerosis Journal

Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis

(2010) Howard L. Zwibel   ADVANCES IN THERAPY

Plasma Cannabinoid Pharmacokinetics following Controlled Oral  9-Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration

(2010) E. L. Karschner et al.   CLINICAL CHEMISTRY

Rehabilitation in practice: Spasticity management

(2010) VL Stevenson   CLINICAL REHABILITATION

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis

(2010) Derick T Wade et al.   Multiple Sclerosis Journal

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

(2010) C. Collin et al.   NEUROLOGICAL RESEARCH

Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain

(2010) David J. Hewitt et al.   PAIN

Emerging strategies for exploiting cannabinoid receptor agonists as medicines

(2009) Roger G Pertwee   BRITISH JOURNAL OF PHARMACOLOGY

National MS registries

(2009) Peter Flachenecker et al.   JOURNAL OF NEUROLOGY

Stop using the Ashworth scale for the assessment of spasticity

(2009) K. S Sunnerhagen   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Stop using the Ashworth Scale for the assessment of spasticity

(2009) J F M Fleuren et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain

(2009) Jeremy R. Johnson et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

(2009) Angelo A. Izzo et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

The Contribution of Cognition and Spasticity to Driving Performance in Multiple Sclerosis

(2008) Thomas D. Marcotte et al.   ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION

Validity, reliability, and clinical importance of change in a 0—10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

(2008) John T. Farrar et al.   CLINICAL THERAPEUTICS

Managing neuropathic pain with Sativex®: a review of its pros and cons

(2008) Jordi Perez et al.   EXPERT OPINION ON PHARMACOTHERAPY

Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors

(2007) G Pryce et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabinoid pharmacology: the first 66 years

(2006) Roger G Pertwee   BRITISH JOURNAL OF PHARMACOLOGY